Volume 13, Number 12—December 2007
Rabies Prophylaxis for Pregnant Women
To the Editor: Rabies poses a 100% risk for death to pregnant women and an indeterminate risk to the fetus (1,2). Although a theoretical risk exists for adverse effects from rabies immune globulin and killed rabies virus vaccines, several studies assessing the safety of this treatment have failed to identify these risks (3–6). Indeed, the consensus is that pregnancy is not a contraindication to rabies postexposure prophylaxis (PEP) (7). Despite this concensus, healthcare providers resist treating pregnant women with rabies PEP. We describe a case of a pregnant woman with uncertain rabies exposure.
A 35-year-old pregnant woman (at 34 weeks gestation) sought treatment 3 weeks after being exposed to a bat. The patient reported awakening at 3:00
The 1999 recommendations of Centers for Disease Control and Prevention Advisory Committee on Immunization Practices state, “... postexposure prophylaxis can be considered for persons who were in the same room as the bat and who might be unaware that a bite or direct contact had occurred ...” (8). Bat bites may not be apparent when they occur, even with careful examination. In fact, most of the recent human rabies patients have no known history of exposure to a rabid animal (9,10). Of the 21 cases of bat-associated rabies in the United States during 1980–1999, 12 (57%) occurred in persons with apparent bat contact but no detectable bites (8). Our patient woke up with a bat flying in her room and did not know how long it had been there. The best course of action would have been to test the bat for rabies. However, because the animal had already been disposed of, laboratory testing for rabies was not possible. Furthermore, given that 5%–9% of bats tested in Washtenaw County, Michigan, are positive for rabies (www.mdch.state.mi.us/pha/epi/cded/cd/batcoframe.htm), the exposure risk was not insignificant. Therefore, it was our opinion that this patient qualified for rabies PEP.
Several studies of the safety of rabies PEP for pregnant patients demonstrated no association between treatment and adverse outcomes (3–6). In 1 study, tissue culture-derived vaccines and human immune globulin did not lead to an increased risk for congenital anomalies; no effects were observed on intrauterine or infant growth or development with a follow-up period of 1 year postpartum (6). Although these studies are not comprehensive in their assessment of all reproductive outcomes, they do suggest that PEP is generally safe.
On the basis of the exposure and our literature review, we recommended that the patient receive rabies PEP. After discussing options with her husband, the patient chose not to receive treatment, citing continued concern about the effect of rabies PEP on the fetus. There must be a greater public health effort to educate clinicians and the public about proper response to bat exposures, particularly undetectable bite exposures such as this case. Had public health authorities been contacted to collect and test the captured bat for rabies, there would have been no ambiguity as to the appropriate course of action.
This research was supported by University of Michigan Medical Scientist Training Program Grant No. GM0786.
- Sipahioglu U, Alpaut S. Transplacental rabies in humans. Mikrobiyol Bul. 1985;19:95–9.
- Muller-Holve W, Leitritz H, Knorr E. Early development of a child following rabies of the mother during pregnancy. Infection. 1977;5:49–50.
- Chutivongse S, Wilde H. Postexposure rabies vaccination during pregnancy: experience with 21 patients. Vaccine. 1989;7:546–8.
- Chutivongse S, Wilde H, Benjavongkulchai M, Chomchey P, Punthawong S. Postexposure rabies vaccination during pregnancy: effect on 202 women and their infants. Clin Infect Dis. 1995;20:818–20.
- Figueroa Damián R, Ortiz-Ibarra FJ, Arredondo-Garcia JL. Post-exposure antirabies prophylaxis in pregnant women [in Spanish]. Ginecol Obstet Mex. 1994;62:13–6.
- Sudarshan MK, Madhusudana SN, Mahendra BJ. Post-exposure prophylaxis with purified vero cell rabies vaccine during pregnancy—safety and immunogenicity. J Commun Dis. 1999;31:229–36.
- American College of Obstetricians and Gynecologists. ACOG Committee opinion. Immunization during pregnancy. Obstet Gynecol. 2003;101:207–12.
- Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Human rabies prevention–United States. MMWR Recomm Rep. 1999;48(RR-1):1–21.
- Rupprecht CE, Gibbons RV. Clinical practice. Prophylaxis against rabies. N Engl J Med. 2004;351:2626–35.
- Messenger SL, Smith JS, Rupprecht CE. Emerging epidemiology of bat associated cryptic cases of rabies in humans in the United States. Clin Infect Dis. 2002;35:738–47.
Suggested citation for this article: Abazeed ME, Cinti, S. Rabies prophylaxis for pregnant women [letter]. Emerg Infect Dis [serial on the Internet]. 2007 Dec [date cited]. Available from http://wwwnc.cdc.gov/eid/article/13/12/07-0157
Please use the form below to submit correspondence to the authors or contact them at the following address:
Sandro Cinti, Infectious Diseases, University of Michigan Hospitals/Ann Arbor VA Health Systems, 2215 Fuller Rd, Ann Arbor, MI 48105, USA;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: July 06, 2010
- Page last updated: July 06, 2010
- Page last reviewed: July 06, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)